Minister Of Health Needs To Accept European Invitation To Join Useful World Leading Cancer Study
Press Release – Prostate Cancer Foundation
Prostate cancer kills over 700 men a year in New Zealand. The Prostate Cancer Foundation of New Zealand says the invitation is significant and useful to mens health. Mr Bedingfield strongly urges the Government to accept.
'Our new Health Minister should take immediate action for men's health on two fronts – he should accept this invitation from Europe, and he should put the minuscule funding into the proposed early detection pilots in the next budget,' Prostate Cancer Foundation of New Zealand President Danny Bedingfield said today.
This follows Europe inviting New Zealand to join the Praise-U consortium, a partnership of institutions from 12 European countries which is co-funded by the European Union. This is a world-leading initiative that aims to enhance the ability for early detection of men with prostate cancer so they can access early treatment to reduce unnecessary early deaths.
Prostate cancer kills over 700 men a year in New Zealand. The Prostate Cancer Foundation of New Zealand says the invitation is significant and useful to men's health. Mr Bedingfield strongly urges the Government to accept.
'Everyone agrees that early detection of cancer leads to better clinical outcomes and saves lives, so why are we not focussing on this with prostate cancer? It makes no sense. We also know that later detection costs the health system more as well. It's a win-win – fewer lives lost unnecessarily, and less cost.
The Foundation recently meet with Health Minister Simeon Brown to seek an initial investment of only $1.6 million a year ($6.4 million over four years) out of the government's circa $30 billion annual health budget to establish a prostate cancer screening pilot in Waitematā and Tairāwhiti. Lessons learned would support an eventual national screening programme. An NZIER report shows that the return on this investment is compelling. It compares very well on a value of money basis to some other health interventions.
Now, in a letter to the Health Minister, Foundation President Danny Bedingfield says joining Praise-U would further assist New Zealand on the pathway to reducing prostate morbidity and mortality in an international context.
'Let's be clear – starting a New Zealand based pilot, which can now be joined into and leverage off this world leading European initiative, will help prevent our men from dying unnecessarily early. And save precious dollars in the health budget!
'New Zealand could learn the lessons from the first two years of Praise-U and share and improve our and Europe's data. This would help us find earlier, and more successfully treat, prostate cancer,' Bedingfield says.
Joining Praise-U would also show New Zealand is a world leader in promoting solutions to men's health and is collaborating internationally.
At the request of the Health Select Committee, the Foundation presented evidence on the benefits of early risk-based screening using the Praise-U model. The Foundation urged the influential committee of MPs to encourage the Minister to sign off the modest spending on two prostate cancer pilots which would feed data to Praise-U.
Bedingfield told the committee there was currently little progress being made on organised early detection of prostate cancer, especially when compared to screening programmes for cervical, breast and bowel cancer.
Prostate cancer is New Zealand's most diagnosed internal cancer, and the second leading cause of cancer death in men behind lung cancer but ahead of bowel cancer.
'New Zealand must actively begin to take steps to tackle prostate cancer if we are to avoid the loss of countless New Zealanders before their time,' Bedingfield says.
In the invitation from Praise-U, coordinator Professor Dr Hein Van Poppel said Praise-U was initially intended to cover only five European pilot sites in Ireland, Lithuania, Poland and two in Spain, but was evolving to a worldwide learning study on screening of prostate cancer.
'New Zealand can learn the vital lessons specific to its own population of at-risk men that can only be learned from pilots in New Zealand, while simultaneously benefitting from and contributing to the knowledge and understanding gathered at the wider community of sites,' van Poppel said.
While optimistic that common sense would see New Zealand accept the invitation, Bedingfield said he would be gutted if it was turned down.
'This and previous governments have shown a great reluctance to support early detection of prostate cancer but joining Praise-U will be a game changer, as it will demonstrate that we are serious about saving our husbands, sons, fathers and friends from succumbing to this deadly disease.
'Our new Health Minister should take action for men's health. There is simply no downside,' Mr Beddingfield concluded.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Otago Daily Times
6 days ago
- Otago Daily Times
Discovery of genes relevant to disease a ‘eureka moment'
University of Otago microbiologist and immunologist Dr Tony Merriman. PHOTO: SUPPLIED Treatment for calcium pyrophosphate deposition (CPPD) disease — more commonly known as inflammatory arthritis — may soon take a major step forward following a major discovery by a University of Otago researcher. There is an unmet need for treatment of CPPD disease, which focuses on the alleviation of inflammation with non-steroidal anti-inflammatory drugs. But University of Otago microbiologist and immunologist Dr Tony Merriman has led an analysis of the genes of 550,000 Americans with the disease, while based at the University of Alabama, Birmingham. It is a first-of-its-kind genome-wide association study into the disease and the research found two genes — RNF144B and ENPP1 — that cause the debilitating calcium pyrophosphate crystal deposits in joints. He said the genes were detected both in people of European ancestry and African ancestry. "The most significant result of our research was the discovery of one of the genes, ENPP1. "The protein encoded by this gene controls the production of chemicals — adenosine monophosphate and inorganic pyrophosphate — that, together with calcium ions, lead to the formation of the CPP crystals," Dr Merriman said. Little is known about the other gene — RNF144B — aside from the possibility it is involved in inflammation. More was known about ENPP1 and of its potential importance to people with CPPD disease. Drugs targeting the protein have been developed in the treatment of infectious disease and cancer and they could now be evaluated for the treatment of CPPD disease. Dr Merriman said the discovery opened up promising new avenues for targeted prevention and treatment of CPPD disease, which were lacking at present. Co-investigator and Brigham and Women's Hospital rheumatology, inflammation and immunity division researcher Dr Sara Tedeschi said the genome-wide association with ENPP1 was "particularly exciting" as a rheumatologist because "it makes sense". "ENPP1 generates inorganic pyrophosphate, one of the components of CPP crystals. "Patients with CPPD disease are desperate for an effective treatment and trials testing ENPP1 inhibitors in CPPD disease would be of great interest." Dr Merriman said the researchers were "thrilled" about the potential impact of their discovery and the possibility of new drugs being developed for the treatment of CPPD disease. "The findings of this study produced a 'eureka moment', which can be rare in a scientist's career."
Scoop
29-05-2025
- Scoop
Smokefree 2025: A Promise Gone Up In Smoke
Press Release – Asthma and Respiratory Foundation of New Zealand As the globe marks World Smokefree Day this Saturday, 31 May, the Asthma and Respiratory Foundation NZ is reminding Kiwis that this was the year New Zealand was meant to become smokefree. Smokefree 2025 was within reach. Now, it's a milestone we're set to miss. As the globe marks World Smokefree Day this Saturday, 31 May, the Asthma and Respiratory Foundation NZ is reminding Kiwis that this was the year New Zealand was meant to become smokefree. 'Instead, the Government rolled back the clock and stoked the fire, derailing years of public health progress,' Foundation Chief Executive Ms Letitia Harding says. Ms Harding says there is little to celebrate and much to be concerned about. 'We were on track to lead the world in tobacco control, now we appear to be leading the world in vaping. 'Our previous Smokefree laws were bold, evidence-based, and targeted at protecting future generations, but the repeal of those measures blindsided everyone.' The Foundation has been one of the strongest advocates for a smokefree Aotearoa for many years. It backed policies that would have phased out tobacco sales for future generations, reduced nicotine levels, and supported drastically cutting the number of retailers. Back in 2021, the Foundation celebrated the bold steps taken toward Smokefree 2025, calling it a 'significant step forward' in reducing respiratory disease and health inequities, particularly for Māori and Pacific communities. Fast forward to today, and the mood has shifted. The Foundation has been vocal in its disappointment over the coalition Government's decision to roll back key Smokefree laws, warning about the implications to the health of New Zealanders and a missed opportunity to lead the world in tobacco control. At the same time, the Foundation is deeply concerned by the new approach to achieving Smokefree Aotearoa – simply shifting the problem to vapes. 'The Government's strategy seems to be 'let's just add vapes to the mix', which is just another product that has harmful health effects and ensures future generations are nicotine dependent,' said Ms Harding. 'As we have said previously, that rationale is like letting stoats in to eradicate rabbits – that's not a solution. 'We're not breaking the cycle of nicotine dependency – we're just redirecting it,' she says. 'Let's free Aotearoa from the shackles of big tobacco, who make money on the back of nicotine dependency.' The goal shouldn't just be a smokefree New Zealand – it should be vape-free too, Ms Harding says. 'Otherwise, we're just chasing a new kind of addiction – and calling it progress.'
Scoop
29-05-2025
- Scoop
Smokefree 2025: A Promise Gone Up In Smoke
Smokefree 2025 was within reach. Now, it's a milestone we're set to miss. As the globe marks World Smokefree Day this Saturday, 31 May, the Asthma and Respiratory Foundation NZ is reminding Kiwis that this was the year New Zealand was meant to become smokefree. "Instead, the Government rolled back the clock and stoked the fire, derailing years of public health progress," Foundation Chief Executive Ms Letitia Harding says. Ms Harding says there is little to celebrate and much to be concerned about. "We were on track to lead the world in tobacco control, now we appear to be leading the world in vaping. "Our previous Smokefree laws were bold, evidence-based, and targeted at protecting future generations, but the repeal of those measures blindsided everyone." The Foundation has been one of the strongest advocates for a smokefree Aotearoa for many years. It backed policies that would have phased out tobacco sales for future generations, reduced nicotine levels, and supported drastically cutting the number of retailers. Back in 2021, the Foundation celebrated the bold steps taken toward Smokefree 2025, calling it a "significant step forward" in reducing respiratory disease and health inequities, particularly for Māori and Pacific communities. Fast forward to today, and the mood has shifted. The Foundation has been vocal in its disappointment over the coalition Government's decision to roll back key Smokefree laws, warning about the implications to the health of New Zealanders and a missed opportunity to lead the world in tobacco control. At the same time, the Foundation is deeply concerned by the new approach to achieving Smokefree Aotearoa - simply shifting the problem to vapes. "The Government's strategy seems to be 'let's just add vapes to the mix', which is just another product that has harmful health effects and ensures future generations are nicotine dependent," said Ms Harding. "As we have said previously, that rationale is like letting stoats in to eradicate rabbits - that's not a solution. "We're not breaking the cycle of nicotine dependency - we're just redirecting it," she says. "Let's free Aotearoa from the shackles of big tobacco, who make money on the back of nicotine dependency." The goal shouldn't just be a smokefree New Zealand - it should be vape-free too, Ms Harding says. "Otherwise, we're just chasing a new kind of addiction - and calling it progress."
